Evidence map›Paper›PMID 25527748›Full record

Trial reportThe American journal of clinical nutrition2015

Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.

Joseph J Lee, Jennifer E Lambert, Yelena Hovhannisyan, Maria A Ramos-Roman, Justin R Trombold, David A Wagner, Elizabeth J Parks

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of clinical nutrition, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01371396 (Effect of Dietary Macronutrient Composition on Liver Substrate Metabolism), which is not on this map. Cited by 98 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 1 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01371396 nacompletednot on this map

Effect of Dietary Macronutrient Composition on Liver Substrate Metabolism

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2007 to 2013Enrolled24ConditionsMetabolic Syndrome, Non-alcoholic Fatty Liver Disease, ObesityArmsLow-fat diet, Low-carbohydrate diet
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Randomized Controlled Trial of a MUFA or Fiber-Rich Diet on Hepatic Fat in Prediabetes.The Journal of clinical endocrinology and metabolism · 2017
    Trial
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. MASH: the nexus of metabolism, inflammation, and fibrosis.The Journal of clinical investigation · 2025
    Review
  17. Targeting Histone Deacetylase 11 with a Highly Selective Inhibitor for the Treatment of MASLD.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  18. Article
  19. Article
  20. Review

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Joseph J LeeFrom the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX (JJL, JEL, YH, and JRT); the Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX (MAR-R); Metabolic Solutions Inc., Nashua, NH (DAW); and the Department of Nutrition and Exercise Physiology, School of Medicine, University of Missouri, Columbia, MO (EJP).
Jennifer E LambertFrom the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX (JJL, JEL, YH, and JRT); the Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX (MAR-R); Metabolic Solutions Inc., Nashua, NH (DAW); and the Department of Nutrition and Exercise Physiology, School of Medicine, University of Missouri, Columbia, MO (EJP).
Yelena HovhannisyanFrom the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX (JJL, JEL, YH, and JRT); the Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX (MAR-R); Metabolic Solutions Inc., Nashua, NH (DAW); and the Department of Nutrition and Exercise Physiology, School of Medicine, University of Missouri, Columbia, MO (EJP).
Maria A Ramos-RomanFrom the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX (JJL, JEL, YH, and JRT); the Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX (MAR-R); Metabolic Solutions Inc., Nashua, NH (DAW); and the Department of Nutrition and Exercise Physiology, School of Medicine, University of Missouri, Columbia, MO (EJP).
Justin R TromboldFrom the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX (JJL, JEL, YH, and JRT); the Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX (MAR-R); Metabolic Solutions Inc., Nashua, NH (DAW); and the Department of Nutrition and Exercise Physiology, School of Medicine, University of Missouri, Columbia, MO (EJP).
David A WagnerFrom the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX (JJL, JEL, YH, and JRT); the Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX (MAR-R); Metabolic Solutions Inc., Nashua, NH (DAW); and the Department of Nutrition and Exercise Physiology, School of Medicine, University of Missouri, Columbia, MO (EJP).
Elizabeth J ParksFrom the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX (JJL, JEL, YH, and JRT); the Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX (MAR-R); Metabolic Solutions Inc., Nashua, NH (DAW); and the Department of Nutrition and Exercise Physiology, School of Medicine, University of Missouri, Columbia, MO (EJP).
Metabolic Solutions · US

Funding

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
UT-Southwestern Clinical and Translational Alliance for Research (UT-STAR) (TL1)UL1TR000451 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2012 to 2012
$6.3M
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1KL2TR001103 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$4.0M
Effect of Dietary Macronutrient Composition and Weight Loss on Liver Substrate MeRL1DK081187 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI PARKS, ELIZABETH JANE · 2007 to 2011
$2.2M
Human Biology Core, Project 10 of 10PL1DK081183 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI BROWNING, JEFFREY D · 2007 to 2011
$1.8M
Taskforce for Obesity Research at Southwestern (TORS)UL1DE019584 · NIDCR · UT SOUTHWESTERN MEDICAL CENTER · PI HORTON, JAY D. · 2008 to 2011
$1.5M
NCATS NIH HHS KL2 TR001103NCATS NIH HHS UL1TR000451NCATS NIH HHS UL1 TR001105NIDCR NIH HHS UL1 DE019584NIDCR NIH HHS UL1DE019584NIDDK NIH HHS 5PL1DK081183NIDDK NIH HHS 5RL1DK081187NIDDK NIH HHS PL1 DK081183NIDDK NIH HHS RL1 DK081187
6 · The paper itself

Abstract

backgroundBiochemical evidence has linked the coordinate control of fatty acid (FA) synthesis with the activity of stearoyl-CoA desaturase-1 (SCD1). The ratio of 16:1n-7 to 16:0 [SCD1₁₆] in plasma triacylglycerol FA has been used as an index to reflect liver SCD1₁₆ activity and has been proposed as a biomarker of FA synthesis, although this use has not been validated by comparison with isotopically measured de novo lipogenesis (DNL(Meas)).

objectiveWe investigated plasma lipid 16:1n-7 and FA indexes of elongation and desaturation in relation to lipogenesis.

designIn this cross-sectional investigation of metabolism, 24 overweight adults, who were likely to have elevated DNL, consumed D2O for 10 d and had liver fat (LF) measured by magnetic resonance spectroscopy. Very-low-density lipoprotein (VLDL)-triacylglycerols and plasma free FA [nonesterified fatty acids (NEFAs)] were analyzed by using gas chromatography for the FA composition (molar percentage) and gas chromatography-mass spectrometry and gas chromatography-combustion isotope ratio mass spectrometry for deuterium enrichment.

resultsIn all subjects, VLDL-triacylglycerol 16:1n-7 was significantly (P < 0.01) related to DNL(Meas) (r = 0.56), liver fat (r = 0.53), and adipose insulin resistance (r = 0.56); similar positive relations were shown with the SCD1₁₆ index, and the pattern in NEFAs echoed that of VLDL-triacylglycerols. Compared with subjects with low LF (3.1 ± 2.7%; n = 11), subjects with high LF (18.4 ± 3.6%; n = 13) exhibited a 45% higher VLDL-triacylglycerol 16:1n-7 molar percentage (P < 0.01), 16% of subjects had lower 18:2n-6 (P = 0.01), and 27% of subjects had higher DNL as assessed by using a published DNL index (ratio of 16:0 to 18:2n-6; P = 0.03), which was isotopically confirmed by DNL(Meas) (increased 2.5-fold; P < 0.01). Compared with 16:0 in the diet, the low amount of dietary 16:1n-7 in VLDL-triacylglycerols corresponded to a stronger signal of elevated DNL.

conclusionThe current data provide support for the use of the VLDL-triacylglycerol 16:1n-7 molar percentage as a biomarker for elevated liver fat when isotope use is not feasible; however, larger-scale confirmatory studies are needed.

Indexed as

LipogenesisUp-RegulationAdiposityAdultAlgorithmsBiomarkersBody Mass IndexCross-Sectional StudiesDeuterium OxideDiet, Fat-RestrictedFatty Acids, MonounsaturatedFatty Acids, NonesterifiedFemaleHumansInsulin ResistanceLipoproteins, VLDLBiomarkersDeuterium OxideFatty Acids, MonounsaturatedFatty Acids, NonesterifiedLipoproteins, VLDLPalmitic Acidpalmitoleic acidSCD1 protein, humanStearoyl-CoA DesaturaseTriglyceridesvery low density lipoprotein triglyceridebiomarkerlipogenesispalmitoleic fatty acidstearoyl-CoA desaturaseVLDL triacylglycerol

Identifiers

PMID25527748
PMCPMC4266891
OpenAlexW2113208048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.